Impact of cyclic citrullinated peptide antibody level on progression to rheumatoid arthritis in clinically tested CCP-positive patients without RA
Arthritis Care & Research Mar 21, 2019
Ford JA, et al. - A sum of 340 candidates were studied to assess the risk of succession to rheumatoid arthritis (RA) in subjects who were cyclic citrullinated antibody positive (CCP+) without RA initially. Authors observed the development of RA in 21.5% of candidates during 1047 person-years of follow-up. They also noticed an incline in the risk of progression to RA with CCP level, with 46.0% of high-level CCP subjects improving to RA by 5 years. Adjusting for age, sex, body mass index, smoking, family history of RA, and rheumatoid factor level, medium and high CCP levels were strongly correlated with progression to RA when compared to low CCP.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries